{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Delgado-Jimenez JF"],"funding":["AstraZeneca Farmacéutica, Spain, S.A."],"pagination":["1170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8910891"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(5)"],"pubmed_abstract":["Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial f"],"journal":["Journal of clinical medicine"],"pubmed_title":["Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics."],"pmcid":["PMC8910891"],"funding_grant_id":["ESR-17-13244"],"pubmed_authors":["Mirabet-Perez S","Bonilla-Palomas JL","Rincon-Diaz LM","Muniz J","Goirigolzarri-Artaza J","Lara-Padron A","Castro-Fernandez A","Delgado-Jimenez JF","Crespo-Leiro MG","Diaz-Molina B","Segovia-Cubero J","Lopez-Fernandez S","Pascual-Figal DA","de Juan-Baguda J","Almenar-Bonet L","Garcia-Pinilla JM","Anguita-Sanchez M","Gomez-Otero I"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.","description":"Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial f","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-22T01:31:04.095Z","creation":"2024-10-15T21:38:46.043Z"},"accession":"S-EPMC8910891","cross_references":{"pubmed":["35268260"],"doi":["10.3390/jcm11051170"]}}